Full Article
Evidence Summary
What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide thisTreating rheumatoid arthritis: Strong recommendations were made for best drugs, but most evidence was not of high quality
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1-26.
Review and guideline question
In people who have rheumatoid arthritis, what are the best recommendations for drug treatments from the American College of Rheumatology (ACR)?
Background
Rheumatoid arthritis is a chronic condition. It causes inflammation of the small joints, usually in the hands and feet. It is an autoimmune disorder that occurs when your own immune system attacks your joints.
Symptoms of rheumatoid arthritis include tender and swollen joints, pain, and stiffness. There is no cure for the condition, and treatment is used to control symptoms and prevent joint damage. Several types of drugs with different side effects are used to treat rheumatoid arthritis. Your doctor will generally prescribe the drugs with the fewest potential side effects first, and try other drugs or combinations of drugs if your symptoms continue or worsen.
How the review was done and recommendations made
The researchers did a systematic review, searching for studies that were published in English up to September 2014. They found 108 systematic reviews, randomized controlled trials, or non-randomized studies.
The key features of the studies were:
- people were 18 years of age or older and had rheumatoid arthritis; and
- drug treatments were traditional disease-modifying antirheumatic drugs (DMARDs) (methotrexate, hydroxychloroquine, leflunomide, sulfasalazine), biologic DMARDs including tumor necrosis factor inhibitors (TNFis) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) and non-TNF biologic drugs (abatacept, rituximab, tocilizumab), and tofacitinib.
A panel of experts, including doctors who specialize in treating arthritis and patient representatives, made recommendations for drug treatments based on the results of the studies, clinical experience, and patient values and preferences. Treatment recommendations could be classified as strong (most patients would want the treatment and few would not) or conditional (more than 50% of patients would want the treatment but many would not). Only the strong recommendations for early (disease or symptom duration of less than 6 months) and established (disease or symptom duration of 6 months of more) rheumatoid arthritis are reported here. Recommendations for people who are considered high risk because of other conditions (e.g., hepatitis B or C infection, congestive heart failure, previous cancer, or previous serious infections) are not reported here.
Conclusion
The American College of Radiology made 8 strong recommendations for drug treatments in rheumatoid arthritis. There wasn’t much high-quality evidence for the treatments.
American College of Rheumatology strong recommendations* for drug treatment in rheumatoid arthritis (RA)
| Groups | Recommendations | Number of trials (quality of evidence) |
| People with early RA or established RA | Use a treat-to-target approach | 1 trial (low quality) in early RA 3 trials (moderate quality) in established RA |
| People with early RA or established RA who have low disease activity and have not previously used DMARDs | Use a DMARD alone (with methotrexate as the preferred drug) | 9 trials‡ (low quality) |
| People with early RA who have moderate or high disease activity despite using a DMARD alone | Use a combination of DMARDs or a TNFi or a nonTNF biologic drug, with or without methotrexate | 3 trials‡ (low quality) |
| People with established RA who have moderate or high disease activity despite using a DMARD alone | Use a combination of DMARDs or add a TNFi, a nonTNF biologic drug, or tofacitinib, with or without methotrexate | 8 trials (high quality) for tofacitinib; 6 trials‡ (moderate to very low quality) for other drugs |
| People with established RA who have moderate or high disease activity despite using a TNFi alone | Add 1 or 2 DMARDs | 6 trials (high quality) |
| People with established RA who have low disease activity but not remission | Continue use of DMARDs, TNFis, nonTNFi biologic drugs, or tofacitinib | 2 trials (high quality) for TNFis 1 trial (moderate quality) for DMARDs 0 trials‡ for other drugs |
| People with established RA that is in remission | Do not stop all drugs used to treat RA | 0 trials‡ |
| People with early or established RA who are using biologic drugs | Use killed/inactivated vaccines (e.g., pneumococcal vaccine) if indicated | 3 trials and 5 other studies‡ (very low quality) |
Related Topics
Glossary
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
-
Surgical interventions for treating hallux valgus and bunions.
Cochrane Database Syst Rev (2024)
-
In older people with knee osteoarthritis, stretching exercise programs can improve pain, stiffness, and physical function disability
Arch Phys Med Rehabil (2023)
-
In people with rheumatoid arthritis, aerobic exercises and/or strength training improve some symptoms
J Adv Nurs (2021)
